880 Shares in Catalent, Inc. (NYSE:CTLT) Purchased by Sentry Investment Management LLC

Sentry Investment Management LLC acquired a new position in Catalent, Inc. (NYSE:CTLT) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 880 shares of the company’s stock, valued at approximately $53,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Catalent by 33.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock valued at $1,230,000 after buying an additional 5,499 shares during the period. BNP Paribas Financial Markets raised its position in Catalent by 154.6% in the first quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock worth $12,211,000 after purchasing an additional 131,360 shares in the last quarter. Nordea Investment Management AB lifted its stake in Catalent by 10.2% during the first quarter. Nordea Investment Management AB now owns 11,874 shares of the company’s stock worth $672,000 after purchasing an additional 1,096 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Catalent by 8.3% during the first quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company’s stock valued at $1,490,000 after purchasing an additional 2,017 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Catalent in the 1st quarter valued at approximately $625,000.

Catalent Trading Down 0.4 %

Shares of NYSE CTLT opened at $58.48 on Wednesday. Catalent, Inc. has a 1-year low of $32.38 and a 1-year high of $61.20. The company has a 50-day moving average of $60.03 and a two-hundred day moving average of $58.02. The company has a market cap of $10.61 billion, a PE ratio of -10.65, a P/E/G ratio of 2.06 and a beta of 1.16. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. As a group, equities analysts expect that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CTLT has been the subject of several analyst reports. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com initiated coverage on shares of Catalent in a research note on Saturday, October 12th. They issued a “hold” rating on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $59.83.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.